Ahmed Altuwiajri

Dr. Ahmed Altuwiajri

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2026 in Cancers
Verified
Journal Article
Open access
PDF file
FAFaris Almutairi
Faris Almutairi
YAYazeed Alneef
Yazeed Alneef
HAHussam Albassam
Hussam Albassam
SASaad Ebrahim Alobid
Saad Ebrahim Alobid
AAAhlam Mohammed Alhusaini
Ahlam Mohammed Alhusaini
SASabry Mohamed Attia
Sabry Mohamed Attia
Background/Objectives: Lipid metabolism dysregulation contributes to cancer progression. Monoacylglycerol lipase (MAGL) breaks down 2-arachidonoylglycerol (2-AG) into glycerol and arachidonic acid, a substrate for cyclooxygenase-2 (COX-2) to produce pro-inflammatory mediators such as prostaglandin E2 (PGE2). Lipopolysaccharide (LPS) activation of Toll-like receptor 4 (TLR4) triggers inflammatory pathways, including COX-2/PGE2 signaling, implicated in diseases such as melanoma. MAGL inhibition reduces prostaglandins and other inflammatory mediators, but its role in inflammation-driven melanoma progression remains unexplored. This study investigated how JZL184, a selective MAGL inhibitor, and 2-AG affect LPS-induced inflammation, proliferation, and migration in B16 melanoma cells. Methods: Cells received LPS alone or with JZL184 or 2-AG. We measured inflammatory transcripts by qRT-PCR, COX-2 protein by Western blot, PGE2 release by ELISA, proliferation by CCK-8, and migration by scratch assay. Results: LPS increased COX-2, PGE2, VEGF, N-cadherin, and inflammatory cytokine expression. JZL184 suppressed these LPS-induced changes and reduced cell proliferation and migration. In contrast, 2-AG did not alter LPS-induced proliferation or inflammatory signals. JZL184’s effects on inflammatory gene expression and proliferation were independent of CB1 receptor signaling, suggesting its anti-melanoma activity may result from reduced inflammatory mediators rather than enhanced endocannabinoid signaling. Conclusions: These findings provide initial evidence that MAGL may regulate inflammation-triggered melanoma progression and could be a plausible therapeutic target.

25 September 2026 in Antioxidants
Verified
Journal Article
Open access
PDF file
NANadrah Alamri
Nadrah Alamri
AAAhlam Mohammed Alhusaini
Ahlam Mohammed Alhusaini
WSWedad Sarawi
Wedad Sarawi
HAHala Attia
Hala Attia
IHIman H Hasan
Iman H Hasan
YAYasser A. Alshawakir
Yasser A. Alshawakir
Renal ischemia/reperfusion injury (RI/RI) is one of the major causes of acute kidney injury (AKI). Low molecular weight-dextran sulphate (LMW-DS) is a bioactive polysaccharide with anti-inflammatory and cytoprotective properties. This study investigated the nephroprotective potential of LMW-DS against the RI/RI. RI/RI rat model underwent surgery that involved a complete bilateral clamping of renal hila for 30 min, followed by unclamping for 30 min. LMW-DS (5 mg/kg, s.c.) was injected 5 min before unclamping. After 24 h, kidneys were collected for biochemical, histopathological, and immunohistochemical examinations. RI/RI dramatically induced renal deterioration, as reflected by marked elevation in the levels of renal oxidative stress, tumor necrosis factor-α, interleukin-6, and toll-like receptor-4, indicating lipid peroxidation and inflammatory response. Furthermore, RI/RI caused upregulation of kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin. Additionally, morphological alterations and collagen deposition were also detected in kidney tissues. The immunohistochemical analysis revealed a strong positive immunoreaction for p38 mitogen-activated protein kinase, c-Jun N-terminal kinase, and caspase-3. Treatment with LMW-DS produced a pronounced amelioration in the altered parameters induced by RI/RI. In conclusion, LMW-DS exerts nephroprotective effects against RI/RI by restoring redox balance, suppressing inflammatory signaling, JNK/p38 MAPK, and caspase-3, highlighting its potential as a therapeutic strategy for renal I/R-induced AKI.

25 June 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
AAAhmed Altuwiajri
Ahmed Altuwiajri
SASarah M. Almufadhili
Sarah M. Almufadhili
TATaher Hashim Almaki
Taher Hashim Almaki
DADalal Ahmed Alkhelb
Dalal Ahmed Alkhelb
SASULTAN ALMUDIMEEGH
SULTAN ALMUDIMEEGH
HSHomood M. As Sobeai
Homood M. As Sobeai
Background/Objectives: Cardiovascular disease increases with ageing and remains the leading cause of death worldwide. Cellular senescence contributes to cardiac dysfunction in the older population by secreting the senescence-associated secretory phenotype (SASP). Cardiac injury models induced by surgery have been shown to induce senescence in young adult rodents. However, surgical models are complex and associated with high mortality. Methods: We established a rat model of injury and senescence using isoproterenol (ISO). Male SD rats received ISO (100 mg/kg) for five days, then hearts were collected on days 10 and 28 after the first ISO dose. Results: ISO administration caused cardiac injury, manifested by inflammatory infiltration, fibrosis, and increased cardiomyocyte cross-sectional area. Cardiac injury was accompanied by an increase in the senescence markers SA-β-gal, p16 and p21, and DNA damage marker γH2AX. Moreover, the mRNA levels of p21 increased on day 10, along with several SASP factors, whereas the mRNA levels of p16 increased on day 28. Fibrosis, hypertrophy, and senescence persisted until day 28, indicating long-lasting cardiac remodeling and senescent cell accumulation. Conclusions: These findings suggest that ISO can provide a simple, cost-effective platform for studying senescence and cardiac injury. This model facilitates the study of timing, dosage, mechanisms and efficacy of senolytic interventions and may contribute to the development of senescence-targeted therapies.

28 September 2026 in Molecules
Verified
Journal Article
Open access
PDF file
DADalal Ahmed Alkhelb
Dalal Ahmed Alkhelb
JAJomana M. Alahmadi
Jomana M. Alahmadi
MAMaisa S. Alqarni
Maisa S. Alqarni
SASyed Rizwan Ahamad
Syed Rizwan Ahamad
AAAlaa Alnoor Alnoor Alameen
Alaa Alnoor Alnoor Alameen
Fawaz AlasmariFawaz Alasmari
Fawaz Alasmari
Background: Opioid use disorder (OUD) remains a critical global health challenge, with highly potent synthetic opioids like fentanyl contributing to overdose deaths. The available treatments have limitations. The endocannabinoid system has emerged steadily as a therapeutic target for the opioid crisis due to its modulatory effects on opioid reward and withdrawal and its involvement in regulating inflammation. These studies investigate the potential of cannabidiol (CBD) and its synthetic derivative (L-1β IN-1) in mitigating fentanyl effects. Methods: C57BL/6 male mice were used in several behavioral assays: two-bottle choice (TBC) to measure fentanyl reward/seeking behaviors, hot plate to assess antinociception, and marble burying to evaluate compulsive/adverse effects. Additionally, a neurometabolic study was conducted to evaluate the impact of chronic high doses of fentanyl alone and in combination with CBD or L-1β-IN-1 on brain metabolic signatures. Results: The mice consistently preferred to drink fentanyl, and i.p. injections of 10 mg/kg CBD or 5–25 mg/kg of L-1β-IN-1 decreased the fentanyl preference scores to values below 0.5. The antinociceptive effects of pretreatment groups showed a trend of enhanced analgesic effects in the hot plate assay. However, they showed no significant changes in the marble-burying assay, suggesting that pretreatment with these compounds lacks acute stereotypic effects. The Fentanyl metabolomics revealed robust metabolic activation with fentanyl alone, while CBD or L-1β-IN-1 showed different profiles in modulating these fentanyl-induced metabolic signatures. Conclusions: These studies provide evidence about the in vivo behavioral and neurometabolic profiles of fentanyl after pretreatment with CBD and synthetic CBD, presenting them as possible pharmacological tools for OUD research.